Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14381787 | 0.91 | PRSS12 (0.64) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381759 | 0.91 | PRSS12 (0.64) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381814 | 0.91 | PRSS12 (0.64) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381762 | 0.91 | PRSS12 (0.64) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381760 | 0.89 | PRSS12 (0.62) | PRSS12CHEK2HDAC6CHEK1LMNA | |
| SCHEMBL14381772 | 0.87 | PRSS12 (0.60) | PRSS12CHEK2HDAC6HDAC3HDAC1 | |
| SCHEMBL14381830 | 0.85 | PRSS12 (0.58) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381836 | 0.85 | PRSS12 (0.58) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381817 | 0.85 | PRSS12 (0.58) | PRSS12CHEK2CHEK1LMNA | |
| SCHEMBL14381791 | 0.85 | PRSS12 (0.58) | PRSS12CHEK2CHEK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282518-B2 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | SIRCAR JAGADISH C | 2007-08-30 | — | — | US | disclosed |
| EP-1368028-B1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IGE AND INHIBITING CELLULAR PROLIFERATION | AVANIR PHARMACEUTICALS (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | SIRCAR JAGADISH C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6759425-B2 | USEFUL IN THE TREATMENT OF ALLERGY AND/OR ASTHMA OR ANY DISEASES WHERE IGE IS PATHOGENIC; ALSO ARE USEFUL AS ANTICANCER AGENTS. | AVANIR PHARMACEUTICALS | 2004-07-06 | — | — | US | disclosed |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | AVANIR PHARMACEUTICALS | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070202133-A1 | BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION | MKI67, CMA1, CCNI | PRSS12 3287/4885CHEK2 2484/4885HDAC6 406/4885 |
| US-20040214821-A1 | Useful in the treatment of allergy and/or asthma or any diseases where Immunoglobulin E (IgE) is pathogenic; anticancer agents | FCER2, CMA1, FCGR1A | PRSS12 3362/4885CHEK2 3296/4885HDAC6 1358/4885 |
| US-20020132808-A1 | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | MKI67, CMA1, CCNI | PRSS12 3287/4885CHEK2 2484/4885HDAC6 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.